Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ONO-4641 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| E1 | EXPERIMENTAL | - |
| E2 | EXPERIMENTAL | - |
| E3 | EXPERIMENTAL | - |
| P | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ONO-4641 | DRUG | 0.15 mg once per day for 26 weeks |
| ONO-4641 placebo | DRUG | Placebo once per day for 26 weeks |
Inclusion Criteria: * Adult male or female aged 18-55 years inclusive at screening * Patients who have a definite diagnosis of relapsing-remitting Multiple Sclerosis Exclusion Criteria: * Multiple Sclerosis course other than relapsing-remitting multiple sclerosis * History of malignancy * History...
ONO-4641 is an investigational small molecule being developed for the treatment of multiple sclerosis. It is currently in Phase 2 clinical development and is not approved by the FDA. The drug is being studied specifically in patients with relapsing-remitting multiple sclerosis.
ONO-4641 is being developed by BrainsWay Ltd., a company traded under the ticker BWAY. The drug is currently in Phase 2 clinical development for multiple sclerosis and remains investigational.
ONO-4641 is in Phase 2 clinical development. It is an investigational drug for multiple sclerosis and has not been approved by the FDA. One Phase 2 trial has been completed, involving 407 patients with relapsing-remitting multiple sclerosis.
ONO-4641 has one completed Phase 2 clinical trial, identified as NCT01081782. This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of ONO-4641 in 407 patients with relapsing-remitting multiple sclerosis across multiple countries.
ONO-4641 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for multiple sclerosis. The drug has completed one Phase 2 trial, but it remains in clinical development and has not received regulatory approval.